Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA
Bristol-Myers Squibb is surrendering its rights to a 30-month stay of approval in litigation over patents issued after an ANDA is on file at FDA